This is one for traders seeking a health care play. Infinity Pharmaceuticals Inc. (NASDAQ: INFI) is a biopharmaceutical company that focuses on developing novel medicines for people with cancer.
It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma. Its product candidate IPI-549 is an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
The company has strategic alliances with the following:
- Intellikine, to discover, develop and commercialize pharmaceutical products targeting the delta or gamma isoforms of PI3K
- Verastem, to research, develop, commercialize and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
- PellePharm, to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate
It also has collaboration agreements with Arcus Biosciences, F. Hoffmann-La Roche and Bristol Myers Squibb.
Wells Fargo started coverage on Infinity Pharmaceuticals stock this week and has a huge $14 price target. The consensus target is $8.50, and shares closed trading at $2.12 on Friday.
This company is in one of the hottest sector silos now, and the stock has outstanding potential. IronSource Ltd. (NYSE: IS) operates a business platform for app developers and telecom operators.
The company’s platforms include Sonic solution suite that supports developers to launch, monetize and scale their apps and games by providing solutions for app discovery, user growth, content monetization, analytics and publishing. Its Aura solution suite allows telecom operators to enrich the device experience by creating new engagement touchpoints that deliver relevant content for their users across the entire lifecycle of the device.
Goldman Sachs has set an $11 price target. This is another company that recently went public via the SPAC route, so there is no consensus price target yet. Since the conversion, the shares have traded between $7.80 and $11.25. The stock closed at $8.53 on Friday.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.